Pfizer to Implement Incyte's Genomic And Microarray Data
Management Software Platforms
Monday September 28, 8:27 am Eastern Time
Company Press Release
SOURCE: Incyte Pharmaceuticals Inc.
PALO ALTO, Calif., Sept. 28 /PRNewswire/ -- Incyte Pharmaceuticals Inc. (Nasdaq: INCY - news) today announced the expansion of its relationship
with Pfizer Inc. (NYSE: PFE - news) to include a license to Incyte's LifeTools(TM) bioinformatics software and LifeArray(TM) microarray data analysis
and management software. Pfizer will implement Incyte's LifeTools bioinformatics software and LifeArray microarray data analysis and management
software to support its global research efforts. Financial terms of the agreement were not disclosed.
The LifeArray software will allow Pfizer researchers to combine Incyte-generated microarray data with microarray data generated from different platforms
into one integrated database of gene expression information. The enterprise-wide software is scalable thus enabling Pfizer researchers all over the world to
combine and analyze microarray data. The data generated from microarray-based experiments can be integrated and compared with sequence data from
the LifeSeq database.
''As costs come down and the use of microarray technology increases, there is a tremendous opportunity in bioinformatics for the management, analysis
and integration of the vast amounts of data that can be generated,'' said Roy A. Whitfield, Chief Executive Officer of Incyte. ''By licensing the LifeArray
and LifeTools platforms, Pfizer has acquired powerful tools for the management of complex genomic data sets.''
The LifeTools genomic data management system will provide Pfizer researchers with the capability to manage genomic data provided by Incyte as well as
from Pfizer's own internal research, track research projects and share data with team members, automate routine tasks, and perform powerful data
analyses.
Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular
basis of disease. The Incyte General division develops and markets gene discovery and expression products -- including databases, genomic data
management software, microarray-based gene expression services, and related reagents -- enabling the pharmaceutical industry to identify new targets and
pathways for drug discovery and development. The Incyte Genetics division will provide databases, bioinformatics, and services relating to sequencing and
mapping the human genome and identifying gene sequence variation, enabling the pharmaceutical industry to utilize pharmacogenetics as an integral part of
pharmaceutical discovery and development. For more information, visit Incyte's web site at incyte.com.
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the
''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Quarterly
Report on Form 10-Q for the quarter ended June 30, 1998. Incyte disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Incyte Pharmaceuticals Inc. |
